GlassScriptPhysician profile
Joe Gorelick
NPI 1811061369
$637,720.37
in general payments reported to CMS, 2019-2025
40 companies · $174K in 2025
The $174K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80K · 2022: $91K · 2023: $131K · 2024: $162K · 2025: $174K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $264K · Consulting Fee: $101K · Travel and Lodging: $56K · Food and Beverage: $30K · Honoraria: $11K · Education: $5,526 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $263,944.75 |
| Consulting Fee | $100,545.53 |
| Travel and Lodging | $55,663.44 |
| Food and Beverage | $30,026.20 |
| Honoraria | $10,587.80 |
| Education | $5,525.65 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $83,969.93 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $67,086.10 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $64,012.04 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $59,776.47 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $55,718.49 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $50,128.27 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $47,357.71 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $40,795.09 | 2021-2025 | Aklief, Epsolay, Oracea |
| E.R. Squibb & Sons, L.L.C. | $32,969.64 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $26,860.03 | 2021-2025 | Levulan Kerastick, Ilumya, Winlevi |
| Genzyme Corporation | $23,641.86 | 2021-2025 | |
| Dermavant Sciences, INC. | $17,054.71 | 2022-2024 | Vtama, Tapinarof |
| Janssen Scientific Affairs, LLC | $11,175.00 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $10,874.88 | 2021-2025 | Dupixent, Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $10,244.21 | 2023-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $6,353.39 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $5,561.09 | 2021-2025 | |
| Eli Lilly and Company | $4,767.52 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $4,427.39 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $4,246.40 | 2021 | |
| Lnhc, INC | $2,783.41 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $1,674.43 | 2021-2025 | |
| Amgen INC. | $1,458.03 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,108.17 | 2022-2024 | Cabtreo, Siliq, Targretin |
| Sanofi US Services INC. | $872.00 | 2025 | |
| Leo Pharma As | $730.75 | 2025 | Adbry |
| Epi Health, LLC | $532.96 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $400.00 | 2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $275.28 | 2021-2024 | Dupixent |
| Allergan, INC. | $167.77 | 2021-2022 | |
| Blueprint Medicines Corporation | $145.08 | 2025 | Ayvakit |
| Revance Therapeutics, INC. | $119.38 | 2025 | Daxxify |
| Almirall LLC | $100.91 | 2023-2025 | Klisyri |
| Journey Medical Corporation | $87.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $62.74 | 2021 | |
| Botanix Sb INC | $50.61 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $43.60 | 2024 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.75 | 2023 | |
| Biofrontera INC. | $27.82 | 2025 | |
| Dermira, INC. | $19.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Gorelick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.